MINNEAPOLIS, May 18, 2021 /PRNewswire/ — Imbio, a leading medical imaging artificial intelligence (AI) provider for chronic lung and cardiothoracic diseases, and Riverain Technologies™, a leader in clinical AI for lung nodules, announce […]
IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of […]
MINNEAPOLIS, April 6, 2021 /PRNewswire/ — Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, and Heart&Lung Health, a leading cardiothoracic consultancy firm, announced their partnership to integrate Imbio AI algorithms […]
MINNEAPOLIS, March 16, 2021 /PRNewswire/ — Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RV/LV Analysis™ algorithm. The […]
MEMPHIS, Tenn., Feb. 24, 2021 /PRNewswire/ — Spesana, a healthcare platform focused for molecular diagnostics-driven decision support and clinical collaboration, and Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging […]
AI-based Software Providing Physicians with Quantitative Evaluation of CT Scans (QCT) for the Non-invasive Determination of Patient Eligibility for the Spiration Valve System Procedure to Treat Severe Emphysema CENTER VALLEY, […]
IntroductionEmphysema severity, emphysema heterogeneity, and pulmonary fissure completeness are predictors of response to endobronchial valve reduction treatment.1 In particular, the assessment of pulmonary fissure completeness is ofparamount importance due to […]
COVID-19 Special Feature – Healthcare Performance Insider How Imbio is using AI to close the gap of missed diagnosis Mike Hostetler lost his father when he was 13 to pancreatic […]
Accumen is helping healthcare get better, faster. Today, 3DR Labs, an Accumen Company, announced that it is now offering an artificial intelligence (AI) solution for diagnosing chronic lung disease through a new partnership with Imbio. 3DR Labs customers will have access to Imbio’s AI imaging technology effective immediately.
Aidoc, the leading provider of enterprise AI solutions, and Imbio, a leading provider of medical image analysis for pulmonary and cardiothoracic diseases, announced today a partnership intended to provide the world’s first end-to-end AI solution for pulmonary embolism (PE), with the goal of ultimately improving efficiency and quality of pulmonary embolism detection and treatment.